This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The study will explore a treatment strategy that includes several medications: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone. These medications are used in combination to treat newly diagnosed patients with Multiple Myeloma. The purpose of the study is to evaluate how well this treatment strategy works in reducing the disease to a minimal level, known as minimal residual disease (MRD), and to see if it can help patients maintain this low level of disease over time.

The study will involve two groups of patients. One group will include patients who have achieved MRD negativity, meaning their disease is at a very low level after initial treatment. The other group will include patients who still have detectable disease. The study will assess how well the treatment helps patients in both groups maintain or achieve MRD negativity. Patients will receive the treatment over a period of time, and their response to the treatment will be monitored regularly. The study will also compare the effects of the treatment with a placebo to understand its effectiveness better.

Throughout the study, patients will receive the medications in different forms, such as tablets or injections, depending on the specific drug. For example, Daratumumab and Bortezomib are given as injections, while Lenalidomide and Dexamethasone are taken orally. The study aims to provide valuable information on how these treatments can help manage Multiple Myeloma and improve patient outcomes. Participants will be closely monitored to ensure their safety and to gather data on the treatment’s effectiveness.